World Journal of Nephrology and Urology, ISSN 1927-1239 print, 1927-1247 online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Nephrol Urol and Elmer Press Inc
Journal website


Volume 8, Number 1, March 2019, pages 8-13

Methicillin-Resistant Staphylococcus aureus Infections in Patients With Renal Disorders: A Review


Table 1. MRSA Risk Groups
Children < 2 years and adults ≥ 65 years
Injection drug users
Military personnel
Inmates of correctional facilities, residential homes or shelters
Veterinarians, pet owners and pig farmers
Patients with post flu-like illness and/or severe pneumonia
Patients with concurrent skin and soft-tissue infections
History of colonization or recent infection with CA-MRSA


Table 2. Limitations of Currently Available Anti-MRSA Antibiotics
Available drugsLimitationsDose adjustment in renal patients
VancomycinMIC creep, hVISA development, variable tissue penetration, and potential for nephrotoxicity at higher concentrations and in combination with other nephrotoxic agentsYes
DaptomycinPotential for decreased susceptibility with increased vancomycin MIC and hVISAYes
LinezolidMultiple potentially serious side effects (marrow suppression, lactic acidosis, peripheral and optic neuropathy, and serotonin syndrome), especially with prolonged useNo
TigecyclineLow serum levels with limited efficacy in bacteremia, black box warning from the US Food and Drug Administration (FDA) for all-cause mortalityNo